紫杉醇联合顺铂腹腔给药与静脉给药治疗Ⅲ~Ⅳ期卵巢癌的疗效及KPS评分对比  

Comparison of efficacy and KPS score of paclitaxel combined with cisplatin intraperitoneal administration and intravenous administration in the treatment of stageⅢ~Ⅳovarian cancer

作　　者：马丹丹 MA Dandan(Department of Gynecology,Luoyang Central Hospital,Luoyang Henan 471000,China)

机构地区：[1]洛阳市中心医院妇科,河南洛阳471000

出　　处：《临床研究》2022年第5期23-27,共5页Clinical Research

摘　　要：目的探讨紫杉醇联合顺铂腹腔给药与静脉给药治疗Ⅲ~Ⅳ期卵巢癌的疗效及卡氏生存质量(KPS)评分。方法选取2019年7月至2021年8月医院收治的78例Ⅲ~Ⅳ期卵巢癌患者,依照随机数表法分为观察组和常规组,每组39例。常规组采用紫杉醇联合顺铂静脉给药治疗,观察组采用紫杉醇联合顺铂腹腔给药治疗。比较两组患者临床疗效,KPS评分、T细胞亚群水平和不良反应。结果治疗3个周期后,观察组客观缓解率高于常规组,差异有统计学意义(P<0.05)。治疗前,两组患者治疗前后KPS评分对比差异无统计学意义(P>0.05),治疗3个周期后,两组患者治疗后KPS评分均升高,且观察组KPS评分高于常规组,差异有统计学意义(P<0.05)。治疗前,两组患者CD4^(+)、CD4^(+)/CD8^(+)比较,差异无统计学意义(P>0.05),治疗3个周期后,两组患者CD4^(+)、CD4^(+)/CD8^(+)较治疗前均降低,差异有统计学意义(P<0.05),且观察组CD4^(+)、CD4^(+)/CD8^(+)高于常规组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论与静脉给药相比,紫杉醇联合顺铂腹腔给药治疗Ⅲ~Ⅳ期卵巢癌疗效显著,能够提高KPS评分,改善免疫功能,安全可靠。Objective To investigate the efficacy and kappa's quality of life(KPS)score of paclitaxel combined with cisplatin in the treatment of stageⅢ~Ⅳovarian cancer.Methods 78 patients with stage Ⅲ~Ⅳ ovarian cancer treated in the hospital from July 2019 to August 2021 were randomly divided into observation group and routine group,with 39 cases in each group.The routine group was treated with paclitaxel combined with cisplatin intravenously,and the observation group was treated with paclitaxel combined with cisplatin intraperitoneally.The clinical efficacy,KPS score,T cell subsets and adverse reactions were compared between the two groups.Results After 3 cycles of treatment,the objective remission rate in the observation group was higher than that in the routine group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in KPS score between the two groups before and after treatment(P>0.05).After 3 cycles of treatment,the KPS score of the two groups increased,and the KPS score of the observation group was higher than that of the routine group,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in CD4^(+) and CD4^(+)/CD8^(+) between the two groups(P>0.05).After 3 cycles of treatment,CD4^(+) and CD4^(+)/CD8^(+) in the two groups decreased significantly(P<0.05),and CD4^(+) and CD4^(+)/CD8^(+) in the observation group were higher than those in the routine group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with intravenous administration,intraperitoneal administration of paclitaxel combined with cisplatin is effective in the treatment of stage Ⅲ~Ⅳ ovarian cancer,which can improve KPS score and immune function,and is safe and reliable.

关 键 词：紫杉醇 顺铂腹腔给药 静脉给药 Ⅲ~Ⅳ期卵巢癌 卡氏生存质量 

分 类 号：R737.31[医药卫生—肿瘤]